Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00503698 · ClinicalTrials.gov registry record · Phase 3
The Effect of Somatropin Treatment in Adult Patients on Chronic Dialysis
A Phase 3 study, sponsored by Novo Nordisk A/S.
- Terminated
- Registry status
- Phase 3
- Development phase
- 712
- Enrollment target
NCT00503698 is a Phase 3 study that was terminated before completion, run by Novo Nordisk A/S. The registered enrollment target is 712 participants.
The verdict
NCT00503698, a Phase 3 study, was terminated before completion, sponsored by Novo Nordisk A/S.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 712 participants
- Enrollment target
Study Summary
This trial is conducted in Africa, Asia, Europe, North and South America and Oceania. The aim of the trial is to evaluate the effect of somatropin (human growth hormone) on survival (primary end-point; "time to death" and health related quality of life in adult patients on chronic haemodialysis.
Interventions
- DRUG placebo
- DRUG somatropin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 712 participants |
| Start Date | 2007-07 |
| Est. Completion | 2008-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00503698
The ClinicalTrials.gov registry entry for NCT00503698 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 712 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00503698 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00503698 about?
NCT00503698 is a clinical study titled "The Effect of Somatropin Treatment in Adult Patients on Chronic Dialysis". This trial is conducted in Africa, Asia, Europe, North and South America and Oceania. The aim of the trial is to evaluate the effect of somatropin (human growth hormone) on survival (primary end-point; "time to death" and health related quality of life in adult patients on chronic haemodialysis.
What is the current status of trial NCT00503698?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 712 participants. The study started on 2007-07. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00503698?
The interventions under investigation include: placebo (DRUG), somatropin (DRUG).
Who is sponsoring clinical trial NCT00503698?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.